SynthesisOpen heart2026
Sex-disaggregated data in hypertrophic cardiomyopathy: a targeted literature review, meta-analysis and primary cohort study.
Synthesis in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy characterised by pathological left ventricular hypertrophy and categorised into obstructive and non-obstructive subtypes. While its autosomal dominant inheritance pattern would suggest similar prevalence, emerging evidence suggests sex-based physiological differences in presentation, progression and outcomes. We sought to better understand these differences in the literature and among our own cohort of patients with HCM.
methodsA targeted literature review (TLR) of MEDLINE and Web of Science, and subsequent meta-analysis of NT-proBNP captured sex-disaggregated echocardiographic and cardiac MRI values, genetic mutation effects, biomarker levels and outcomes. A retrospective study of patients diagnosed with HCM at University Hospitals Coventry and Warwickshire NHS Trust, UK between January 2007 and January 2025 examined sex-based differences in presentation, diagnosis and outcomes in HCM.
resultsThe TLR found that females were older at diagnosis and had significantly lower septal and left ventricular wall thickness and left ventricular mass. The meta-analysis showed males had lower NT-proBNP levels than females, potentially reflecting sex-based differences in cardiovascular stress. In our cohort (n=207) comprising 78 (38%) females, age at diagnosis was higher (59.4±20.5 vs 53.5±16.1 years; p=0.026) among females than males, with no significant baseline differences in ethnicity, HCM subtype or social deprivation. Maximal wall thickness was higher in males (21.7±6.8 vs 18.2±2.9 mm; p=0.007). Females had higher rates of septal reduction therapy (44.1% vs 19.6%; p=0.018). Mortality was higher among females (20.5% vs 9.3%; p=0.022; 28 deaths at end of follow-up) though adjusted analyses did not reach significance (HR 2.09, 95% CI 0.998, 4.45; p=0.057).
conclusionsThe findings from our cohort support the results of the TLR that females tend to be diagnosed with HCM later than males and experience worse symptoms and outcomes. Further research should clarify the implications of sex-based disparities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.